Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	antigen binding	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IGHV3-66	4.44e-09	190	80	10	GO:0003823
GeneOntologyMolecularFunction	glutamate-gated receptor activity	GRIA2 GRIA3 GRIN1 GRIN3A	5.46e-07	17	80	4	GO:0004970
GeneOntologyMolecularFunction	glutamate receptor activity	GRIA2 GRIA3 GRIN1 GRIN3A	3.91e-06	27	80	4	GO:0008066
GeneOntologyMolecularFunction	transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	GRIA2 GRIA3 GRIN1 GRIN3A	8.03e-05	57	80	4	GO:1904315
GeneOntologyMolecularFunction	AMPA glutamate receptor activity	GRIA2 GRIA3	9.46e-05	4	80	2	GO:0004971
GeneOntologyMolecularFunction	neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential	GRIA2 GRIA3 GRIN1 GRIN3A	9.82e-05	60	80	4	GO:0099529
GeneOntologyMolecularFunction	ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	GRIA2 GRIA3 GRIN1	1.18e-04	24	80	3	GO:0099507
GeneOntologyMolecularFunction	transmitter-gated channel activity	GRIA2 GRIA3 GRIN1 GRIN3A	1.34e-04	65	80	4	GO:0022835
GeneOntologyMolecularFunction	transmitter-gated monoatomic ion channel activity	GRIA2 GRIA3 GRIN1 GRIN3A	1.34e-04	65	80	4	GO:0022824
GeneOntologyMolecularFunction	postsynaptic neurotransmitter receptor activity	GRIA2 GRIA3 GRIN1 GRIN3A	2.34e-04	75	80	4	GO:0098960
GeneOntologyMolecularFunction	double-stranded RNA adenosine deaminase activity	ADAD2 ADAR	2.35e-04	6	80	2	GO:0003726
GeneOntologyMolecularFunction	ligand-gated calcium channel activity	GRIA3 GRIN1 ITPR1	2.57e-04	31	80	3	GO:0099604
GeneOntologyMolecularFunction	extracellular ligand-gated monoatomic ion channel activity	GRIA2 GRIA3 GRIN1 GRIN3A	2.59e-04	77	80	4	GO:0005230
GeneOntologyMolecularFunction	double-stranded RNA binding	ADAD2 AGO1 AGO4 ADAR	2.72e-04	78	80	4	GO:0003725
GeneOntologyMolecularFunction	glutamate-gated calcium ion channel activity	GRIA3 GRIN1	4.37e-04	8	80	2	GO:0022849
GeneOntologyMolecularFunction	tRNA-specific adenosine deaminase activity	ADAD2 ADAR	4.37e-04	8	80	2	GO:0008251
GeneOntologyMolecularFunction	NMDA glutamate receptor activity	GRIN1 GRIN3A	4.37e-04	8	80	2	GO:0004972
GeneOntologyMolecularFunction	neurotransmitter receptor activity	GRIA2 GRIA3 GRIN1 GRIN3A	7.00e-04	100	80	4	GO:0030594
GeneOntologyMolecularFunction	amino acid transmembrane transporter activity	GRIA2 GRIA3 GRIN1 GRIN3A	8.40e-04	105	80	4	GO:0015171
GeneOntologyMolecularFunction	ligand-gated monoatomic ion channel activity	GRIA2 GRIA3 GRIN1 GRIN3A ITPR1	1.07e-03	193	80	5	GO:0015276
GeneOntologyMolecularFunction	ligand-gated channel activity	GRIA2 GRIA3 GRIN1 GRIN3A ITPR1	1.17e-03	197	80	5	GO:0022834
GeneOntologyMolecularFunction	adenosine deaminase activity	ADAD2 ADAR	1.20e-03	13	80	2	GO:0004000
GeneOntologyMolecularFunction	glycine binding	GRIN1 GRIN3A	1.40e-03	14	80	2	GO:0016594
GeneOntologyMolecularFunction	glucosidase activity	MGAM LCT	1.61e-03	15	80	2	GO:0015926
GeneOntologyMolecularFunction	calcium channel activity	GRIA3 GRIN1 GRIN3A ITPR1	1.80e-03	129	80	4	GO:0005262
GeneOntologyMolecularFunction	NADP binding	DECR1 FMO4 PGD	1.98e-03	62	80	3	GO:0050661
GeneOntologyMolecularFunction	ligand-gated monoatomic cation channel activity	GRIA2 GRIA3 GRIN1 ITPR1	2.42e-03	140	80	4	GO:0099094
GeneOntologyMolecularFunction	calcium ion transmembrane transporter activity	GRIA3 GRIN1 GRIN3A ITPR1	3.18e-03	151	80	4	GO:0015085
GeneOntologyBiologicalProcess	immunoglobulin mediated immune response	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IGHV3-66	2.20e-08	235	79	10	GO:0016064
GeneOntologyBiologicalProcess	B cell mediated immunity	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IGHV3-66	3.15e-08	244	79	10	GO:0019724
GeneOntologyBiologicalProcess	ligand-gated ion channel signaling pathway	GRIA2 GRIA3 GRIN1 GRIN3A ITPR1	4.30e-07	40	79	5	GO:1990806
GeneOntologyBiologicalProcess	lymphocyte mediated immunity	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IL4I1 IGHV3-66	1.10e-06	449	79	11	GO:0002449
GeneOntologyBiologicalProcess	adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IL4I1 IGHV3-66	1.45e-06	462	79	11	GO:0002460
GeneOntologyBiologicalProcess	ionotropic glutamate receptor signaling pathway	GRIA2 GRIA3 GRIN1 GRIN3A	3.27e-06	27	79	4	GO:0035235
GeneOntologyBiologicalProcess	RISC complex assembly	AGO1 AGO4 ADAR	6.37e-06	10	79	3	GO:0070922
GeneOntologyBiologicalProcess	leukocyte mediated immunity	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IL4I1 IGHV3-66	1.19e-05	576	79	11	GO:0002443
GeneOntologyBiologicalProcess	negative regulation of response to external stimulus	CYLD CACTIN HDAC6 PDGFRA SIGLEC8 GRIN1 GRIN3A PTGER4 ADAR MEFV	2.40e-05	509	79	10	GO:0032102
GeneOntologyBiologicalProcess	pre-miRNA processing	AGO1 AGO4 ADAR	3.54e-05	17	79	3	GO:0031054
GeneOntologyBiologicalProcess	glutamate receptor signaling pathway	GRIA2 GRIA3 GRIN1 GRIN3A	7.73e-05	59	79	4	GO:0007215
GeneOntologyBiologicalProcess	adaptive immune response	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IL4I1 IGHV3-66	7.82e-05	838	79	12	GO:0002250
GeneOntologyBiologicalProcess	disaccharide catabolic process	MGAM LCT	8.65e-05	4	79	2	GO:0046352
GeneOntologyBiologicalProcess	siRNA-mediated post-transcriptional gene silencing	AGO1 AGO4	8.65e-05	4	79	2	GO:0140766
GeneOntologyBiologicalProcess	siRNA-mediated gene silencing by mRNA destabilization	AGO1 AGO4	8.65e-05	4	79	2	GO:0090625
GeneOntologyBiologicalProcess	immune effector process	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 PTGER4 IL4I1 IGHV3-66	9.89e-05	859	79	12	GO:0002252
GeneOntologyBiologicalProcess	polysaccharide metabolic process	PHKA2 MGAM WDR45 STBD1 PTGER4	1.23e-04	126	79	5	GO:0005976
GeneOntologyBiologicalProcess	synaptic transmission, glutamatergic	HDAC6 GRIA2 GRIA3 GRIN1 GRIN3A	1.53e-04	132	79	5	GO:0035249
GeneOntologyBiologicalProcess	response to glycine	GRIA2 GRIN1	2.15e-04	6	79	2	GO:1905429
GeneOntologyBiologicalProcess	adenosine to inosine editing	ADAD2 ADAR	3.00e-04	7	79	2	GO:0006382
GeneOntologyBiologicalProcess	glucan catabolic process	MGAM WDR45 STBD1	3.52e-04	36	79	3	GO:0009251
GeneOntologyBiologicalProcess	negative regulation of hydrogen peroxide metabolic process	HDAC6 PTGER4	4.00e-04	8	79	2	GO:0010727
GeneOntologyBiologicalProcess	polysaccharide catabolic process	MGAM WDR45 STBD1	4.14e-04	38	79	3	GO:0000272
GeneOntologyBiologicalProcess	response to amphetamine	HDAC6 GRIN1 RGS7	4.82e-04	40	79	3	GO:0001975
GeneOntologyBiologicalProcess	RNA secondary structure unwinding	AGO1 AGO4	5.12e-04	9	79	2	GO:0010501
GeneOntologyBiologicalProcess	glucan metabolic process	PHKA2 MGAM WDR45 STBD1	6.14e-04	101	79	4	GO:0044042
GeneOntologyBiologicalProcess	regulation of postsynaptic membrane potential	GRIA2 GRIA3 GRIN1 GRIN3A RGS7	6.40e-04	180	79	5	GO:0060078
GeneOntologyCellularComponent	immunoglobulin complex	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IGHV3-66	7.75e-10	166	80	10	GO:0019814
GeneOntologyCellularComponent	ionotropic glutamate receptor complex	GRIA2 GRIA3 GRIN1 GRIN3A	2.63e-05	45	80	4	GO:0008328
GeneOntologyCellularComponent	neurotransmitter receptor complex	GRIA2 GRIA3 GRIN1 GRIN3A	4.01e-05	50	80	4	GO:0098878
GeneOntologyCellularComponent	spliceosomal complex	CACTIN RBMXL3 DDX42 CWC25 ADAR AQR	1.76e-04	215	80	6	GO:0005681
GeneOntologyCellularComponent	NMDA selective glutamate receptor complex	GRIN1 GRIN3A	5.12e-04	9	80	2	GO:0017146
GeneOntologyCellularComponent	RISC-loading complex	AGO1 AGO4	6.38e-04	10	80	2	GO:0070578
GeneOntologyCellularComponent	external side of plasma membrane	CD3G STAB2 PDGFRA SIGLEC8 GRIA2 ITGA7 LCT MOG	8.28e-04	519	80	8	GO:0009897
GeneOntologyCellularComponent	microtubule	CYLD HDAC6 PDE4DIP NAV3 TTLL8 CSPP1 DNAH9 MEFV	9.83e-04	533	80	8	GO:0005874
GeneOntologyCellularComponent	cell surface	GPC1 CD3G STAB2 PDGFRA SIGLEC8 MRC2 GRIA2 ERP29 GRIN1 ITGA7 LCT MOG	1.02e-03	1111	80	12	GO:0009986
GeneOntologyCellularComponent	fascia adherens	XIRP1 DSP	1.10e-03	13	80	2	GO:0005916
GeneOntologyCellularComponent	ficolin-1-rich granule membrane	MGAM STBD1 DSP	1.66e-03	61	80	3	GO:0101003
GeneOntologyCellularComponent	Set1C/COMPASS complex	HCFC2 HCFC1	1.68e-03	16	80	2	GO:0048188
GeneOntologyCellularComponent	side of membrane	GPC1 CYLD CD3G STAB2 PDGFRA SIGLEC8 GRIA2 ITGA7 LCT MOG	1.82e-03	875	80	10	GO:0098552
GeneOntologyCellularComponent	plasma membrane signaling receptor complex	CD3G GRIA2 GRIA3 GRIN1 GRIN3A ITGA7	2.24e-03	350	80	6	GO:0098802
Domain	Iontro_rcpt	GRIA2 GRIA3 GRIN1 GRIN3A	5.02e-07	18	69	4	IPR001320
Domain	Lig_chan-Glu_bd	GRIA2 GRIA3 GRIN1 GRIN3A	5.02e-07	18	69	4	PF10613
Domain	Iono_rcpt_met	GRIA2 GRIA3 GRIN1 GRIN3A	5.02e-07	18	69	4	IPR001508
Domain	Glu/Gly-bd	GRIA2 GRIA3 GRIN1 GRIN3A	5.02e-07	18	69	4	IPR019594
Domain	Lig_chan-Glu_bd	GRIA2 GRIA3 GRIN1 GRIN3A	5.02e-07	18	69	4	SM00918
Domain	Lig_chan	GRIA2 GRIA3 GRIN1 GRIN3A	5.02e-07	18	69	4	PF00060
Domain	PBPe	GRIA2 GRIA3 GRIN1 GRIN3A	5.02e-07	18	69	4	SM00079
Domain	Peripla_BP_I	GRIA2 GRIA3 GRIN1 GRIN3A	1.27e-05	39	69	4	IPR028082
Domain	Argonaute_N	AGO1 AGO4	8.03e-05	4	69	2	IPR032474
Domain	Argonaute_Mid_dom	AGO1 AGO4	8.03e-05	4	69	2	IPR032473
Domain	ArgoL2	AGO1 AGO4	8.03e-05	4	69	2	IPR032472
Domain	ArgoN	AGO1 AGO4	8.03e-05	4	69	2	PF16486
Domain	ArgoMid	AGO1 AGO4	8.03e-05	4	69	2	PF16487
Domain	ArgoL2	AGO1 AGO4	8.03e-05	4	69	2	PF16488
Domain	DUF1785	AGO1 AGO4	1.34e-04	5	69	2	SM01163
Domain	ArgoL1	AGO1 AGO4	2.00e-04	6	69	2	PF08699
Domain	ADEAMc	ADAD2 ADAR	2.00e-04	6	69	2	SM00552
Domain	ArgoL1	AGO1 AGO4	2.00e-04	6	69	2	IPR014811
Domain	A_deamin	ADAD2 ADAR	2.00e-04	6	69	2	PF02137
Domain	A_DEAMIN_EDITASE	ADAD2 ADAR	2.00e-04	6	69	2	PS50141
Domain	A_deamin	ADAD2 ADAR	2.00e-04	6	69	2	IPR002466
Domain	ANF_lig-bd_rcpt	GRIA2 GRIA3 GRIN1	3.43e-04	37	69	3	IPR001828
Domain	ANF_receptor	GRIA2 GRIA3 GRIN1	3.43e-04	37	69	3	PF01094
Domain	PIWI	AGO1 AGO4	3.71e-04	8	69	2	PS50822
Domain	Piwi	AGO1 AGO4	3.71e-04	8	69	2	SM00950
Domain	Piwi	AGO1 AGO4	3.71e-04	8	69	2	IPR003165
Domain	Piwi	AGO1 AGO4	3.71e-04	8	69	2	PF02171
Domain	PAZ	AGO1 AGO4	4.76e-04	9	69	2	PS50821
Domain	PAZ	AGO1 AGO4	4.76e-04	9	69	2	SM00949
Domain	PAZ_dom	AGO1 AGO4	4.76e-04	9	69	2	IPR003100
Domain	PAZ	AGO1 AGO4	4.76e-04	9	69	2	PF02170
Domain	DOCK_C	DOCK5 DOCK9	7.24e-04	11	69	2	IPR010703
Domain	DHR-1_domain	DOCK5 DOCK9	7.24e-04	11	69	2	IPR027007
Domain	DHR_2	DOCK5 DOCK9	7.24e-04	11	69	2	PS51651
Domain	DHR_1	DOCK5 DOCK9	7.24e-04	11	69	2	PS51650
Domain	DOCK-C2	DOCK5 DOCK9	7.24e-04	11	69	2	PF14429
Domain	DHR-2	DOCK5 DOCK9	7.24e-04	11	69	2	IPR027357
Domain	DHR-2	DOCK5 DOCK9	7.24e-04	11	69	2	PF06920
Domain	DOCK	DOCK5 DOCK9	7.24e-04	11	69	2	IPR026791
Domain	Kelch_2	HCFC2 HCFC1	1.02e-03	13	69	2	IPR011498
Domain	Kelch_2	HCFC2 HCFC1	1.02e-03	13	69	2	PF07646
Domain	DSRM	ADAD2 ADAR	2.21e-03	19	69	2	SM00358
Domain	dsrm	ADAD2 ADAR	2.45e-03	20	69	2	PF00035
Domain	DS_RBD	ADAD2 ADAR	2.70e-03	21	69	2	PS50137
Domain	-	CD3G STBD1 PDGFRA SIGLEC8 KIRREL1 HCFC2 HCFC1 MOG	3.00e-03	663	69	8	2.60.40.10
Domain	Ig-like_fold	CD3G STBD1 PDGFRA SIGLEC8 KIRREL1 HCFC2 HCFC1 MOG	4.39e-03	706	69	8	IPR013783
Domain	-	HCFC2 HCFC1	4.45e-03	27	69	2	2.130.10.80
Domain	-	ADAD2 ADAR	4.45e-03	27	69	2	3.30.160.20
Domain	dsRBD_dom	ADAD2 ADAR	4.78e-03	28	69	2	IPR014720
Domain	Kringle-like	MRC2 MST1L	6.21e-03	32	69	2	IPR013806
Domain	Gal_Oxidase_b-propeller	HCFC2 HCFC1	6.99e-03	34	69	2	IPR015916
Pathway	REACTOME_FCGR_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	8.91e-13	48	66	9	MM17214
Pathway	REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66 ITPR1	2.31e-12	53	66	9	MM15716
Pathway	REACTOME_CD22_MEDIATED_BCR_REGULATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	3.17e-12	35	66	8	MM17219
Pathway	REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	3.91e-12	56	66	9	MM14815
Pathway	REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 STAB2 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	7.52e-12	60	66	9	MM14872
Pathway	REACTOME_CLASSICAL_ANTIBODY_MEDIATED_COMPLEMENT_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	8.17e-12	39	66	8	MM17212
Pathway	REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.80e-11	45	66	8	MM14912
Pathway	REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.31e-10	54	66	8	MM14655
Pathway	REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.37e-10	58	66	8	MM14914
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	3.15e-10	60	66	8	MM14913
Pathway	REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 SIGLEC8 IGHV3-66	6.20e-10	135	66	10	MM14781
Pathway	REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.71e-09	114	66	9	MM14814
Pathway	REACTOME_COMPLEMENT_CASCADE	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	4.91e-09	84	66	8	MM14653
Pathway	REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66 ITPR1	9.27e-09	131	66	9	MM15717
Pathway	REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	3.37e-08	107	66	8	MM14915
Pathway	REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	GPC1 IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	4.76e-08	158	66	9	MM14812
Pathway	REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 ITPR1	1.03e-07	82	66	7	M27110
Pathway	REACTOME_FCGR3A_MEDIATED_IL10_SYNTHESIS	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 ITPR1	2.84e-07	95	66	7	M29842
Pathway	REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	4.64e-07	150	66	8	MM14889
Pathway	REACTOME_FCGR_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23	7.95e-07	69	66	6	M27108
Pathway	WP_NRXN1_DELETION_SYNDROME	GRIA2 GRIA3 GRIN1 GRIN3A	1.28e-06	18	66	4	M48098
Pathway	REACTOME_HEMOSTASIS	GPC1 DOCK5 IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 DOCK9 DGKG IGHV3-66 ITPR1	1.96e-06	571	66	13	MM14472
Pathway	REACTOME_ANTI_INFLAMMATORY_RESPONSE_FAVOURING_LEISHMANIA_PARASITE_INFECTION	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 ITPR1	2.93e-06	134	66	7	M29840
Pathway	REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 ITPR1	2.93e-06	86	66	6	M601
Pathway	REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 ITPR1	2.93e-06	86	66	6	M27206
Pathway	REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 ITPR1	4.51e-06	143	66	7	M27107
Pathway	REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 STAB2 IGHV3-23	6.28e-06	98	66	6	M27152
Pathway	REACTOME_LEISHMANIA_INFECTION	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 MEFV ITPR1	7.91e-06	219	66	8	M29836
Pathway	REACTOME_CD22_MEDIATED_BCR_REGULATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	9.37e-06	61	66	5	M27581
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	IGHV3-53 CYLD IGHV3-48 MGAM IGHV3-33 CD3G IGHV3-30 IGHV3-23 STBD1 IGHV3-21 IGHV3-20 DSP SIGLEC8 LTA4H MEFV IGHV3-66	1.00e-05	995	66	16	MM14661
Pathway	REACTOME_PARASITE_INFECTION	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23	1.66e-05	116	66	6	M29843
Pathway	REACTOME_SCAVENGING_OF_HEME_FROM_PLASMA	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	1.72e-05	69	66	5	M27150
Pathway	REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	1.98e-05	71	66	5	M1078
Pathway	REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	1.98e-05	71	66	5	M27203
Pathway	REACTOME_ACTIVATION_OF_NMDA_RECEPTORS_AND_POSTSYNAPTIC_EVENTS	GRIA2 GRIA3 GRIN1 GRIN3A	2.06e-05	35	66	4	MM15109
Pathway	REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 SIGLEC8	2.88e-05	190	66	7	M8240
Pathway	REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	3.54e-05	80	66	5	M6121
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	5.30e-05	87	66	5	M27205
Pathway	REACTOME_ADAPTIVE_IMMUNE_SYSTEM	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 SIGLEC8 MRC2 IGHV3-66 ITPR1	1.10e-04	719	66	12	MM14540
Pathway	REACTOME_UNBLOCKING_OF_NMDA_RECEPTORS_GLUTAMATE_BINDING_AND_ACTIVATION	GRIA2 GRIA3 GRIN1	1.23e-04	21	66	3	M838
Pathway	REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 ITPR1	1.23e-04	166	66	6	M608
Pathway	WP_PKCGAMMA_CALCIUM_SIGNALING_IN_ATAXIA	GRIA2 GRIA3 ITPR1	1.42e-04	22	66	3	M39795
Pathway	REACTOME_UNBLOCKING_OF_NMDA_RECEPTORS_GLUTAMATE_BINDING_AND_ACTIVATION	GRIA2 GRIA3 GRIN1	1.42e-04	22	66	3	MM15104
Pathway	REACTOME_VESICLE_MEDIATED_TRANSPORT	IGHV3-53 IGHV3-48 IGHV3-33 CD3G IGHV3-30 STAB2 IGHV3-23 IGHV3-21 IGHV3-20 ALS2CL IGHV3-66	1.83e-04	645	66	11	MM15232
Pathway	REACTOME_COMPLEMENT_CASCADE	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	1.99e-04	115	66	5	M19752
Pathway	BIOCARTA_DICER_PATHWAY	AGO1 AGO4	2.14e-04	5	66	2	M22079
Pathway	REACTOME_ASSEMBLY_AND_CELL_SURFACE_PRESENTATION_OF_NMDA_RECEPTORS	GRIN1 GRIN3A	2.14e-04	5	66	2	MM15655
Pathway	REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 ITPR1	2.29e-04	186	66	6	M27175
Pathway	REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	GPC1 IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	2.88e-04	194	66	6	M16312
Pathway	REACTOME_MICRORNA_MIRNA_BIOGENESIS	AGO1 AGO4	3.20e-04	6	66	2	MM14818
Pathway	REACTOME_POST_TRANSCRIPTIONAL_SILENCING_BY_SMALL_RNAS	AGO1 AGO4	3.20e-04	6	66	2	MM15083
Pathway	REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	4.33e-04	136	66	5	M27207
Pathway	REACTOME_POST_TRANSCRIPTIONAL_SILENCING_BY_SMALL_RNAS	AGO1 AGO4	4.47e-04	7	66	2	M46421
Pathway	REACTOME_SMALL_INTERFERING_RNA_SIRNA_BIOGENESIS	AGO1 AGO4	5.94e-04	8	66	2	MM15082
Pathway	REACTOME_DIGESTION_OF_DIETARY_CARBOHYDRATE	MGAM LCT	5.94e-04	8	66	2	MM14717
Pathway	REACTOME_FORMATION_OF_WDR5_CONTAINING_HISTONE_MODIFYING_COMPLEXES	HCFC2 HCFC1 AKAP8L	7.36e-04	38	66	3	MM17073
Pathway	REACTOME_SMALL_INTERFERING_RNA_SIRNA_BIOGENESIS	AGO1 AGO4	7.61e-04	9	66	2	M27340
Pathway	REACTOME_REGULATION_OF_PTEN_MRNA_TRANSLATION	AGO1 AGO4	7.61e-04	9	66	2	M27810
Pathway	REACTOME_REGULATION_OF_NPAS4_MRNA_TRANSLATION	AGO1 AGO4	7.61e-04	9	66	2	M46436
Pathway	REACTOME_POTENTIAL_THERAPEUTICS_FOR_SARS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23	7.62e-04	154	66	5	M39007
Pathway	WP_COMMON_PATHWAYS_UNDERLYING_DRUG_ADDICTION	GRIA2 GRIA3 GRIN1	9.20e-04	41	66	3	M39655
Pathway	REACTOME_REGULATION_OF_CDH11_MRNA_TRANSLATION_BY_MICRORNAS	AGO1 AGO4	9.48e-04	10	66	2	M48013
Pathway	REACTOME_ACTIVATION_OF_NMDA_RECEPTORS_AND_POSTSYNAPTIC_EVENTS	GRIA2 GRIA3 GRIN1 GRIN3A	9.74e-04	94	66	4	M2843
Pathway	REACTOME_FORMATION_OF_WDR5_CONTAINING_HISTONE_MODIFYING_COMPLEXES	HCFC2 HCFC1 AKAP8L	9.88e-04	42	66	3	M48018
Pathway	REACTOME_HEMOSTASIS	GPC1 DOCK5 IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 DOCK9 DGKG ITPR1	1.15e-03	679	66	10	M8395
Pathway	REACTOME_DIGESTION_OF_DIETARY_CARBOHYDRATE	MGAM LCT	1.16e-03	11	66	2	M1091
Pathway	WP_ADHD_AND_AUTISM_ASD_PATHWAYS	WDR45 PDGFRA GRIA2 GRIA3 GRIN1 GRIN3A HCFC1	1.59e-03	367	66	7	M48346
Pathway	WP_LEUKOTRIENE_METABOLIC_PATHWAY	DECR1 LTA4H	1.63e-03	13	66	2	M45552
Pathway	REACTOME_REGULATION_OF_NPAS4_GENE_EXPRESSION	AGO1 AGO4	1.63e-03	13	66	2	M46434
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	IGHV3-53 CYLD IGHV3-48 MGAM IGHV3-33 CD3G IGHV3-30 IGHV3-23 STBD1 DSP LTA4H MEFV ITPR1	1.93e-03	1128	66	13	M1036
Pathway	WP_OMEGA6FATTY_ACIDS_IN_SENESCENCE	DECR1 LTA4H PTGER4	2.39e-03	57	66	3	M48332
Pathway	REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS	GRIA2 GRIA3	2.48e-03	16	66	2	MM15048
Pathway	REACTOME_REGULATION_OF_RUNX1_EXPRESSION_AND_ACTIVITY	AGO1 AGO4	2.81e-03	17	66	2	M27788
Pathway	REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS	GRIA2 GRIA3	2.81e-03	17	66	2	M5488
Pathway	REACTOME_CA2_PATHWAY	AGO1 AGO4 ITPR1	3.04e-03	62	66	3	M27321
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_MECP2	AGO1 AGO4 GRIA2	3.19e-03	63	66	3	M27862
Pathway	REACTOME_REGULATION_OF_MITF_M_DEPENDENT_GENES_INVOLVED_IN_APOPTOSIS	AGO1 AGO4	3.51e-03	19	66	2	M48238
Pathway	KEGG_MEDICUS_REFERENCE_TCR_PLCG_ITPR_SIGNALING_PATHWAY	CD3G ITPR1	3.51e-03	19	66	2	M47733
Pathway	REACTOME_SYNAPTIC_ADHESION_LIKE_MOLECULES	GRIA3 GRIN1	3.88e-03	20	66	2	MM15485
Pathway	WP_NEUROINFLAMMATION_AND_GLUTAMATERGIC_SIGNALING	GRIA2 GRIA3 GRIN1 GRIN3A	4.17e-03	140	66	4	M42572
Pathway	REACTOME_SYNAPTIC_ADHESION_LIKE_MOLECULES	GRIA3 GRIN1	4.28e-03	21	66	2	M27736
Pathway	REACTOME_DIGESTION	MGAM LCT	4.28e-03	21	66	2	MM15526
Pathway	KEGG_LONG_TERM_DEPRESSION	GRIA2 GRIA3 ITPR1	4.29e-03	70	66	3	M8232
Pathway	KEGG_LONG_TERM_POTENTIATION	GRIA2 GRIN1 ITPR1	4.29e-03	70	66	3	M3115
Pathway	REACTOME_NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION	GRIA2 GRIA3 GRIN1 GRIN3A	4.61e-03	144	66	4	MM14501
Pathway	REACTOME_BIOSYNTHESIS_OF_SPECIALIZED_PRORESOLVING_MEDIATORS_SPMS	CYP3A43 LTA4H	4.69e-03	22	66	2	MM15614
Pubmed	1.3 A X-ray structure of an antibody Fv fragment used for induced membrane-protein crystallization.	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	3.47e-18	15	80	8	12657787
Pubmed	Early onset of somatic mutation in immunoglobulin VH genes during the primary immune response.	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.70e-16	22	80	8	2499654
Pubmed	IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes.	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.61e-13	77	80	9	15608191
Pubmed	The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-20 IGHV3-66	3.99e-11	91	80	8	9841928
Pubmed	Structure and physical map of 64 variable segments in the 3'0.8-megabase region of the human immunoglobulin heavy-chain locus.	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-23 IGHV3-20	3.07e-08	39	80	5	8490662
Pubmed	Genetic Deletion of GABAA Receptors Reveals Distinct Requirements of Neurotransmitter Receptors for GABAergic and Glutamatergic Synapse Development.	GRIA2 GRIA3 GRIN1	4.68e-08	4	80	3	31231192
Pubmed	The cell-autonomous role of excitatory synaptic transmission in the regulation of neuronal structure and function.	GRIA2 GRIA3 GRIN1	4.68e-08	4	80	3	23664612
Pubmed	Distribution of alpha-amino-3-hydroxy-5-methyl-4 isoazolepropionic acid and N-methyl-D-aspartate receptor subunits in the vestibular and spiral ganglia of the mouse during early development.	GRIA2 GRIA3 GRIN1	4.68e-08	4	80	3	12414093
Pubmed	Oligodendrocytes as regulators of neuronal networks during early postnatal development.	GRIA2 GRIA3 GRIN1	1.17e-07	5	80	3	21589880
Pubmed	Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B.	CYLD PTPA HDAC6	2.33e-07	6	80	3	20593489
Pubmed	Genetic inhibition of neurotransmission reveals role of glutamatergic input to dopamine neurons in high-effort behavior.	GRIA2 GRIA3 GRIN1	2.33e-07	6	80	3	28194005
Pubmed	Mossy Cells Control Adult Neural Stem Cell Quiescence and Maintenance through a Dynamic Balance between Direct and Indirect Pathways.	GRIA2 GRIA3 GRIN1	2.33e-07	6	80	3	30057205
Pubmed	Glutamate can act as a signaling molecule in mouse preimplantation embryos†.	GRIA2 GRIA3 GRIN1 GRIN3A	2.66e-07	24	80	4	35746896
Pubmed	Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking.	GRIA2 GRIA3 GRIN1	4.07e-07	7	80	3	17093100
Pubmed	The CREB/CREM transcription factors negatively regulate early synaptogenesis and spontaneous network activity.	GRIA2 GRIA3 GRIN1	6.51e-07	8	80	3	19144833
Pubmed	Loss of postsynaptic GABA(A) receptor clustering in gephyrin-deficient mice.	GRIA2 GRIA3 GRIN1	9.75e-07	9	80	3	10531433
Pubmed	Changes of several brain receptor complexes in the cerebral cortex of patients with Alzheimer disease: probable new potential pharmaceutical targets.	GRIA2 GRIA3 GRIN1	9.75e-07	9	80	3	24292102
Pubmed	Impaired reproductive behavior by lack of GluR-B containing AMPA receptors but not of NMDA receptors in hypothalamic and septal neurons.	GRIA2 GRIN1	5.23e-06	2	80	2	16099814
Pubmed	Synaptic inhibition in the olfactory bulb accelerates odor discrimination in mice.	GRIA2 GRIN1	5.23e-06	2	80	2	20159452
Pubmed	Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors.	GRIN1 GRIN3A	5.23e-06	2	80	2	11160393
Pubmed	The Importance of AGO 1 and 4 in Post-Transcriptional Gene Regulatory Function of tRF5-GluCTC, an Respiratory Syncytial Virus-Induced tRNA-Derived RNA Fragment.	AGO1 AGO4	5.23e-06	2	80	2	33233493
Pubmed	Molecular interaction of NMDA receptor subunit NR3A with protein phosphatase 2A.	PTPA GRIN3A	5.23e-06	2	80	2	15194871
Pubmed	Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex.	GRIN1 GRIN3A	5.23e-06	2	80	2	18296432
Pubmed	Involvement of AMPA receptor GluR2 and GluR3 trafficking in trigeminal spinal subnucleus caudalis and C1/C2 neurons in acute-facial inflammatory pain.	GRIA2 GRIA3	5.23e-06	2	80	2	22937151
Pubmed	Functional interplay between cylindromatosis and histone deacetylase 6 in ciliary homeostasis revealed by phenotypic analysis of double knockout mice.	CYLD HDAC6	5.23e-06	2	80	2	27028867
Pubmed	Synaptic transmission and plasticity in the absence of AMPA glutamate receptor GluR2 and GluR3.	GRIA2 GRIA3	5.23e-06	2	80	2	12848940
Pubmed	Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?	GRIA2 GRIA3	5.23e-06	2	80	2	19933774
Pubmed	GluR2-free alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors intensify demyelination in experimental autoimmune encephalomyelitis.	GRIA2 GRIA3	5.23e-06	2	80	2	17472701
Pubmed	Supralinear potentiation of NR1/NR3A excitatory glycine receptors by Zn2+ and NR1 antagonist.	GRIN1 GRIN3A	5.23e-06	2	80	2	18711142
Pubmed	Involvement of GluR2 and GluR3 subunit C-termini in the trigeminal spinal subnucleus caudalis and C1-C2 neurons in trigeminal neuropathic pain.	GRIA2 GRIA3	5.23e-06	2	80	2	21215292
Pubmed	Formation of NR1/NR2 and NR1/NR3 heterodimers constitutes the initial step in N-methyl-D-aspartate receptor assembly.	GRIN1 GRIN3A	5.23e-06	2	80	2	17959602
Pubmed	N-methyl-D-aspartate receptor subunit NR3A in the retina: developmental expression, cellular localization, and functional aspects.	GRIN1 GRIN3A	5.23e-06	2	80	2	14507892
Pubmed	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease.	GRIA2 GRIN1	5.23e-06	2	80	2	25104560
Pubmed	Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A.	GRIN1 GRIN3A	5.23e-06	2	80	2	9620802
Pubmed	Effects of Echinococcus multilocularis miR-71 mimics on murine macrophage RAW264.7 cells.	AGO1 AGO4	5.23e-06	2	80	2	26995025
Pubmed	Endocytosis and recycling of AMPA receptors lacking GluR2/3.	GRIA2 GRIA3	5.23e-06	2	80	2	18195348
Pubmed	Excitatory GluN1/GluN3A glycine receptors (eGlyRs) in brain signaling.	GRIN1 GRIN3A	5.23e-06	2	80	2	37248111
Pubmed	Structural features in the glycine-binding sites of the GluN1 and GluN3A subunits regulate the surface delivery of NMDA receptors.	GRIN1 GRIN3A	5.23e-06	2	80	2	31444392
Pubmed	Simultaneous analysis of dendritic spine density, morphology and excitatory glutamate receptors during neuron maturation in vitro by quantitative immunocytochemistry.	GRIA2 GRIN1	5.23e-06	2	80	2	22521963
Pubmed	Activation-induced structural change in the GluN1/GluN3A excitatory glycine receptor.	GRIN1 GRIN3A	5.23e-06	2	80	2	25017909
Pubmed	Evolutionarily conserved intercalated disc protein Tmem65 regulates cardiac conduction and connexin 43 function.	GPC1 XIRP1 DSP	5.23e-06	15	80	3	26403541
Pubmed	Adjacent asparagines in the NR2-subunit of the NMDA receptor channel control the voltage-dependent block by extracellular Mg2+.	GRIA2 GRIA3 GRIN1	5.23e-06	15	80	3	9481670
Pubmed	Early Correction of N-Methyl-D-Aspartate Receptor Function Improves Autistic-like Social Behaviors in Adult Shank2-/- Mice.	GRIA2 GRIN1 GRIN3A	6.42e-06	16	80	3	30466882
Pubmed	Prenatal expression of D-aspartate oxidase causes early cerebral D-aspartate depletion and influences brain morphology and cognitive functions at adulthood.	GRIA2 GRIA3 GRIN1	7.79e-06	17	80	3	32185508
Pubmed	BDNF regulates spontaneous correlated activity at early developmental stages by increasing synaptogenesis and expression of the K+/Cl- co-transporter KCC2.	GRIA2 GRIA3 GRIN1	9.33e-06	18	80	3	12588844
Pubmed	Arhgap22 Disruption Leads to RAC1 Hyperactivity Affecting Hippocampal Glutamatergic Synapses and Cognition in Mice.	GRIA2 GRIA3 GRIN1	9.33e-06	18	80	3	34455539
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	DECR1 CYLD DSP DOCK9 PDE4DIP NAV3 DGKG GRIA2 GRIA3 GRIN1 AKAP8L ITPR1	1.11e-05	1139	80	12	36417873
Pubmed	NMDAR-dependent presynaptic homeostasis in adult hippocampus: Synapse growth and cross-modal inhibitory plasticity.	GRIA2 GRIA3	1.57e-05	3	80	2	36070750
Pubmed	NMDA receptor-dependent recruitment of calnexin to the neuronal plasma membrane.	GRIA2 ITPR1	1.57e-05	3	80	2	23851254
Pubmed	An inhalation anaesthesia approach for neonatal mice allowing streamlined stereotactic injection in the brain.	GRIA2 GRIA3	1.57e-05	3	80	2	32569783
Pubmed	Long-term potentiation reconstituted with an artificial TARP/PSD-95 complex.	GRIA2 GRIA3	1.57e-05	3	80	2	36223737
Pubmed	Persistent synaptic scaling independent of AMPA receptor subunit composition.	GRIA2 GRIA3	1.57e-05	3	80	2	23864664
Pubmed	AMPA receptor anchoring at CA1 synapses is determined by N-terminal domain and TARP γ8 interactions.	GRIA2 GRIA3	1.57e-05	3	80	2	34426577
Pubmed	Subunit-specific roles of glycine-binding domains in activation of NR1/NR3 N-methyl-D-aspartate receptors.	GRIN1 GRIN3A	1.57e-05	3	80	2	17047094
Pubmed	Linking supply to demand: the neuronal monocarboxylate transporter MCT2 and the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid receptor GluR2/3 subunit are associated in a common trafficking process.	GRIA2 GRIA3	1.57e-05	3	80	2	19453627
Pubmed	Activity-dependent NMDA receptor degradation mediated by retrotranslocation and ubiquitination.	GRIA2 GRIN1	1.57e-05	3	80	2	15809437
Pubmed	Opposing gradients of ribbon size and AMPA receptor expression underlie sensitivity differences among cochlear-nerve/hair-cell synapses.	GRIA2 GRIA3	1.57e-05	3	80	2	21248103
Pubmed	GluA2 (GluR2) regulates metabotropic glutamate receptor-dependent long-term depression through N-cadherin-dependent and cofilin-mediated actin reorganization.	GRIA2 GRIA3	1.57e-05	3	80	2	21248105
Pubmed	Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage.	GRIA2 GRIA3	1.57e-05	3	80	2	15144856
Pubmed	The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn.	GRIA2 GRIA3	1.57e-05	3	80	2	9892356
Pubmed	Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis.	XIRP1 ALS2CL	1.57e-05	3	80	2	20657180
Pubmed	Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients.	GRIA2 GRIA3	1.57e-05	3	80	2	18163426
Pubmed	Glutamate receptor subunit 3 is modified by site-specific limited proteolysis including cleavage by gamma-secretase.	GRIA2 GRIA3	1.57e-05	3	80	2	12700243
Pubmed	Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors.	GRIA2 GRIA3	1.57e-05	3	80	2	23595422
Pubmed	Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development.	GRIN1 GRIN3A	1.57e-05	3	80	2	22238099
Pubmed	Neural mechanism underlies CYLD modulation of morphology and synaptic function of medium spiny neurons in dorsolateral striatum.	CYLD GRIA2	1.57e-05	3	80	2	36846565
Pubmed	Control of aversion by glycine-gated GluN1/GluN3A NMDA receptors in the adult medial habenula.	GRIN1 GRIN3A	1.57e-05	3	80	2	31601771
Pubmed	AMPA receptor alterations precede mossy fiber sprouting in young children with temporal lobe epilepsy.	GRIA2 GRIA3	1.57e-05	3	80	2	15145077
Pubmed	Synaptic transmission and plasticity require AMPA receptor anchoring via its N-terminal domain.	GRIA2 GRIA3	1.57e-05	3	80	2	28290985
Pubmed	Potentiation of synaptic AMPA receptors induced by the deletion of NMDA receptors requires the GluA2 subunit.	GRIA2 GRIN1	1.57e-05	3	80	2	20980546
Pubmed	Long-term upregulation of cortical glutamatergic AMPA receptors in a mouse model of chronic visceral pain.	GRIA2 GRIA3	1.57e-05	3	80	2	26585043
Pubmed	Glutamatergic plasticity by synaptic delivery of GluR-B(long)-containing AMPA receptors.	GRIA2 GRIA3	1.57e-05	3	80	2	14687553
Pubmed	Synaptic homeostasis requires the membrane-proximal carboxy tail of GluA2.	GRIA2 GRIA3	1.57e-05	3	80	2	29180434
Pubmed	Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.	IGHV3-48 IGHV3-21	1.57e-05	3	80	2	33036024
Pubmed	Cardiac Fibro-Adipocyte Progenitors Express Desmosome Proteins and Preferentially Differentiate to Adipocytes Upon Deletion of the Desmoplakin Gene.	PDGFRA DSP	1.57e-05	3	80	2	27121621
Pubmed	A ternary complex comprising FAK, PTPα and IP3 receptor 1 functionally engages focal adhesions and the endoplasmic reticulum to mediate IL-1-induced Ca2+ signalling in fibroblasts.	PTPA ITPR1	1.57e-05	3	80	2	26611753
Pubmed	Modulation of ADAR mRNA expression in patients with congenital heart defects.	GRIA2 ADAR	1.57e-05	3	80	2	31039163
Pubmed	Neuronal enriched endosomal protein of 21 kDa colocalizes with glutamate receptor subunit GLUR2/3 at the postsynaptic membrane.	GRIA2 GRIA3	1.57e-05	3	80	2	19063943
Pubmed	Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach.	GRIA2 GRIA3	1.57e-05	3	80	2	19409270
Pubmed	Synaptic targeting of AMPA receptors is regulated by a CaMKII site in the first intracellular loop of GluA1.	GRIA2 GRIA3	1.57e-05	3	80	2	21135237
Pubmed	Novel anchorage of GluR2/3 to the postsynaptic density by the AMPA receptor-binding protein ABP.	GRIA2 GRIA3	1.57e-05	3	80	2	9768844
Pubmed	Subunit-specific role for the amino-terminal domain of AMPA receptors in synaptic targeting.	GRIA2 GRIA3	1.57e-05	3	80	2	28630296
Pubmed	Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins.	AGO1 AGO4	1.57e-05	3	80	2	19946268
Pubmed	Synapse-specific control of experience-dependent plasticity by presynaptic NMDA receptors.	GRIN1 GRIN3A	1.57e-05	3	80	2	25144876
Pubmed	LTP requires a reserve pool of glutamate receptors independent of subunit type.	GRIA2 GRIA3	1.57e-05	3	80	2	23235828
Pubmed	Chromosomal localization of glutamate receptor genes: relationship to familial amyotrophic lateral sclerosis and other neurological disorders of mice and humans.	GRIA2 GRIA3 GRIN1	2.01e-05	23	80	3	8464923
Pubmed	A phylogenetic analysis reveals an unusual sequence conservation within introns involved in RNA editing.	GRIA2 GRIA3	3.13e-05	4	80	2	10688364
Pubmed	Analysis of NR3A receptor subunits in human native NMDA receptors.	GRIN1 GRIN3A	3.13e-05	4	80	2	17997397
Pubmed	Molecular dissection of human Argonaute proteins by DNA shuffling.	AGO1 AGO4	3.13e-05	4	80	2	23748378
Pubmed	Signalling through AMPA receptors on oligodendrocyte precursors promotes myelination by enhancing oligodendrocyte survival.	GRIA2 GRIA3	3.13e-05	4	80	2	28608780
Pubmed	GSG1L suppresses AMPA receptor-mediated synaptic transmission and uniquely modulates AMPA receptor kinetics in hippocampal neurons.	GRIA2 GRIA3	3.13e-05	4	80	2	26932439
Pubmed	The majority of A-to-I RNA editing is not required for mammalian homeostasis.	GRIA2 ADAR	3.13e-05	4	80	2	31815657
Pubmed	AMPA receptor subunits expressed by single astrocytes in the juvenile mouse hippocampus.	GRIA2 GRIA3	3.13e-05	4	80	2	9221927
Pubmed	Interaction proteomics reveals brain region-specific AMPA receptor complexes.	GRIA2 GRIA3	3.13e-05	4	80	2	25337787
Pubmed	Auditory sensitivity regulation via rapid changes in expression of surface AMPA receptors.	GRIA2 GRIA3	3.13e-05	4	80	2	17828255
Pubmed	Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.	AGO1 AGO4	3.13e-05	4	80	2	15260970
Pubmed	The N-terminal domain modulates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization.	GRIA2 GRIA3	3.13e-05	4	80	2	24652293
Pubmed	Electrophysiological properties of AMPA receptors are differentially modulated depending on the associated member of the TARP family.	GRIA2 GRIA3	3.13e-05	4	80	2	17409242
Pubmed	AMPA receptor deletion in developing MGE-derived hippocampal interneurons causes a redistribution of excitatory synapses and attenuates postnatal network oscillatory activity.	GRIA2 GRIA3	3.13e-05	4	80	2	31992779
Pubmed	Enhanced ethanol inhibition of recombinant N-methyl-D-aspartate receptors by magnesium: role of NR3A subunits.	GRIN1 GRIN3A	3.13e-05	4	80	2	18445116
Interaction	GRIN3A interactions	PTPA GRIN1 GRIN3A	5.83e-06	10	75	3	int:GRIN3A
Cytoband	14q32.33	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IGHV3-66	9.10e-12	228	80	10	14q32.33
Cytoband	Ensembl 112 genes in cytogenetic band chr14q32	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	6.59e-07	566	80	9	chr14q32
Cytoband	16p13.3	TIGD7 PRSS22 ANKS3 MEFV	8.97e-04	244	80	4	16p13.3
Cytoband	12q23.3	STAB2 HCFC2	1.72e-03	35	80	2	12q23.3
Cytoband	Ensembl 112 genes in cytogenetic band chr12q23	STAB2 LTA4H HCFC2	2.34e-03	150	80	3	chr12q23
Cytoband	Xq25	DCAF12L1 GRIA3	2.35e-03	41	80	2	Xq25
Cytoband	Ensembl 112 genes in cytogenetic band chrXq25	DCAF12L1 GRIA3	3.21e-03	48	80	2	chrXq25
GeneFamily	Immunoglobulin heavy locus at 14q32.33	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-30-5 IGHV3-66	3.74e-10	187	58	10	349
GeneFamily	Glutamate ionotropic receptor AMPA type subunits	GRIA2 GRIA3	6.04e-05	4	58	2	1200
GeneFamily	Glutamate ionotropic receptor NMDA type subunits	GRIN1 GRIN3A	2.10e-04	7	58	2	1201
GeneFamily	Argonaute/PIWI family	AGO1 AGO4	2.80e-04	8	58	2	408
GeneFamily	Adenosine deaminases acting on RNA	ADAD2 ADAR	2.80e-04	8	58	2	1303
Coexpression	XU_CREBBP_TARGETS_DN	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 ADAR IGHV3-66	8.66e-14	56	79	9	MM642
Coexpression	YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 DSP IGHV3-66	2.34e-11	102	79	9	MM872
Coexpression	RASHI_RESPONSE_TO_IONIZING_RADIATION_6	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	6.45e-09	132	79	8	MM996
Coexpression	GSE22229_RENAL_TRANSPLANT_IMMUNOSUPP_THERAPY_VS_HEALTHY_PBMC_DN	GPC1 MGAM DSP LTA4H ERP29 MEFV ITPR1	2.39e-06	199	79	7	M7479
Coexpression	NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN	DOCK5 STAB2 STBD1 MAST4 PDGFRA SIGLEC8 PRSS22 DGKG KIRREL1 CWC25 AKAP8L MOG	1.70e-05	909	79	12	M41018
Coexpression	GSE18148_CBFB_KO_VS_WT_TREG_DN	XIRP1 NAV3 DGKG GRIN1 SH3RF3 MOG	3.20e-05	200	79	6	M4252
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_500_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	2.08e-05	163	73	6	Arv_SC-hpx_blastocyst_500_K2
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	3.10e-05	175	73	6	Arv_SC-H9hpx_500_K3
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_1000_k-means-cluster#5	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	3.98e-05	183	73	6	Arv_SC_fibroblast_1000_K5
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_1000_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	3.98e-05	183	73	6	Arv_SC-HD_1000_K3
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_500_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	7.39e-05	126	73	5	Arv_SC-HD_500_K2
CoexpressionAtlas	DevelopingKidney_e15.5_Peripheral blastema_emap-27731_k-means-cluster#3_top-relative-expression-ranked_1000	COL5A2 STBD1 DCAF12L1 PDGFRA KIRREL1 HCFC2 AQR	8.88e-05	307	73	7	gudmap_developingKidney_e15.5_Peripheral blastema_1000_k3
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.18e-04	139	73	5	Arv_SC_fibroblast_500_K3
CoexpressionAtlas	BM Top 100 - hippocampus	ST6GALNAC5 GRIA2 GRIA3 MOG	1.51e-04	78	73	4	BM Top 100 - hippocampus
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_1000_k-means-cluster#4	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	1.94e-04	244	73	6	Arv_SC-H9hpx_1000_K4
ToppCell	367C-Lymphocytic-Plasma_cell-\|367C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.77e-11	167	79	9	f2185eb72f0137136f6d71af2a70168fded6c940
ToppCell	367C-Lymphocytic-Plasma_cell\|367C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.77e-11	167	79	9	5e768cf24699893e05d1bcb1c92dba2336943a64
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	3.65e-11	181	79	9	e47664a264a2c37390d1668ce04eef2e0172f4cb
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Plasma_cells\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	5.63e-11	190	79	9	79ee6d10dfbb775da149a1104da5823cf63bbb46
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Plasma_cells-IgA_plasma_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	5.63e-11	190	79	9	18762ce78ed0b206ade19e1c8ff76a2647489f68
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	6.48e-11	193	79	9	34f6c13884fdf7f8a87f942fcb36a58cfac3f65d
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	6.48e-11	193	79	9	282b47dae6043eabb1e13d41d91c07b5ec21cd65
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	6.78e-11	194	79	9	6ef4aeb8d8e35e4df58ff2a8256caa2113291de9
ToppCell	Biopsy_IPF-Immune-Plasma_cells\|Biopsy_IPF / Sample group, Lineage and Cell type	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	7.43e-11	196	79	9	a1b6a8000b86efcb07843998aa3a49bb1f54bcda
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	7.78e-11	197	79	9	2662138671262b30508c5759038bcdcfe6551696
ToppCell	Mild_COVID-19-B_cell\|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.31e-09	183	79	8	dea119e2988e954475f557f0bbe12556a83e81a4
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.37e-09	184	79	8	15f2c10101ccc8ed059520fc082ee42593dff269
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.37e-09	184	79	8	a90a58d9e319afa1cd572e4c2f516fadc42f56e5
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.43e-09	185	79	8	08bc817908076734d66f2805cb954141f2cc5a18
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.43e-09	185	79	8	1704a12153a9b107bf03ecccd1a036cf61334d7a
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.08e-09	194	79	8	a4a70369541876e1192df8828b63e3d1746ae3d9
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.16e-09	195	79	8	13f4ee21568fd747608412d33559d10561dbb3c8
ToppCell	Biopsy_Other_PF-Immune-Plasma_cells\|Biopsy_Other_PF / Sample group, Lineage and Cell type	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.16e-09	195	79	8	d0305c6a68c9e361507b04db94f86873085d49b3
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	2.16e-09	195	79	8	f3f7f1a77a1edd2b50a8211c76fe289738eb04cf
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	2.16e-09	195	79	8	df009b18898c10686f75cf72b4ec0eff18f5bb50
ToppCell	COVID_vent-Lymphocytic-Plasma_cell-IgM_Plasmablast\|COVID_vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.25e-09	196	79	8	026a06d8d2089806823e6f6453d3ede84ae93bc6
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.34e-09	197	79	8	1e63879633f20646e44873ae6b662f6faf4806fd
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.34e-09	197	79	8	9fe1b757f76c2d43d39aa9ac500eaba98723985c
ToppCell	3'_v3-bone_marrow-Lymphocytic_B_plasma-Plasma_cells\|bone_marrow / Manually curated celltypes from each tissue	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	2.73e-08	175	79	7	51301f3f44d3e88397f367cedd1e2abaa2be4c6f
ToppCell	COPD-Lymphoid-B_Plasma\|World / Disease state, Lineage and Cell class	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	2.73e-08	175	79	7	d73ee324479172501481b54967a0f3bd870fcf3a
ToppCell	metastatic_Brain-B_lymphocytes-MALT_B_cells\|metastatic_Brain / Location, Cell class and cell subclass	IGHV3-53 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.84e-08	176	79	7	50e207403d48ce1b55a78897adb5519a2430a626
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	2.96e-08	177	79	7	4c434a7b7cc54cf4dac996bbc3f5124d9ef9a9cd
ToppCell	(2)_Plasma_cells\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	2.96e-08	177	79	7	ed3c936bb69f9bc7291b4f6cde1d204078117c48
ToppCell	VE-plasma\|VE / Condition, Cell_class and T cell subcluster	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	2.96e-08	177	79	7	0c1cc0834de55717cb4f69d020339060ce2c9a03
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	2.96e-08	177	79	7	d746122bf8d208c3aa4d156e8c12d0a0e555c6e5
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	2.96e-08	177	79	7	fc40918825b7e1eb6861df59dfca944778a64b98
ToppCell	VE-plasma-\|VE / Condition, Cell_class and T cell subcluster	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	2.96e-08	177	79	7	3a3c94cf30012e2aa266bc4d7fe772e45fa90f6d
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	3.07e-08	178	79	7	107dae8b00c4257697a63700e72bb434cdb8406f
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	3.19e-08	179	79	7	837ed81f18257f444eaeadc4fac89deedd4e3061
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	3.19e-08	179	79	7	494febe77c6d4e6a2c6f0928bbf4c84b0301f188
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	3.19e-08	179	79	7	b6ee4f41d8fb5f047b7bdd8489dda0a89fc6d43f
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL DNAH9	3.72e-08	183	79	7	3c516fe5083f02bad1f464ed284010b4131a833c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL DNAH9	3.72e-08	183	79	7	9c2689d76fc6d30f5ab093428aa669d0a98953cf
ToppCell	cellseq-Immune-Lymphocytic_B-Lymphocytic_B-Plasma\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	3.72e-08	183	79	7	5ab4aa0304b832f98fff89b6c24ad5b7dd014c11
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	3.86e-08	184	79	7	3f8a359e40bebe58545f708682e5e5d1b70cf5cb
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	3.86e-08	184	79	7	64bede8db709fd32f40c03265b96f0b12155bb8a
ToppCell	BAL-Mild-Lymphocyte-B-B_cell\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	4.00e-08	185	79	7	609080adb2cfb105bb7b8efb617553833299f371
ToppCell	Mild_COVID-19-B_cell-B_cell\|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	4.16e-08	186	79	7	855a5a00ba2aa1b5c63b8db56d026ddecc546050
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	5.35e-08	193	79	7	5c5543e7c83ecea44d23521246592c0301044173
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	5.95e-08	196	79	7	c38e7f533c619afe008de0e99042f7180c2da918
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	5.95e-08	196	79	7	e9fe5090452ffdde4bb81b62d57037d823281d00
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	5.95e-08	196	79	7	fec21383435779bf4c632decd3d29c6ca7baebfb
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	6.16e-08	197	79	7	88b29d205237f07a9a26cc15a1cf4ed4816a4c4b
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_cell\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	6.16e-08	197	79	7	76465bb2408c7c75f694e8f7cf1a606b796afc3a
ToppCell	Biopsy_Control_(H.)-Immune-Plasma_cells\|Biopsy_Control_(H.) / Sample group, Lineage and Cell type	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	6.16e-08	197	79	7	275f38ed7e477000e864cecf9b7d49ae134c3b6a
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell-IgG_Plasmablast\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	6.16e-08	197	79	7	b754fad4f3caae6de95df901fd96ea8697fe41b1
ToppCell	COVID-19-lung-Fibroblast\|lung / Disease (COVID-19 only), tissue and cell type	COL5A2 NEBL PDGFRA MRC2 ST6GALNAC5 NAV3 KIRREL1	6.37e-08	198	79	7	df3de77216f5c5d6141ec44d01c56b942f611838
ToppCell	BAL-Mild-Lymphocyte-B\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	5.69e-07	169	79	6	307571e57c3bfdf15f0fe1a8b36585e8e4f8a207
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21	6.53e-07	173	79	6	0ca2169a275404118038c0489a48062879488765
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-1\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 DSP ITPR1	7.22e-07	176	79	6	ad05dd934f4ac2e656b3455de091f4c8772de6c8
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	7.46e-07	177	79	6	4d2cdb57b427a42085c5f9affa0967b15e84dec3
ToppCell	-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	IGHV3-53 IGHV3-49 IGHV3-48 IGHV3-23 IGHV3-21 IGHV3-20	7.46e-07	177	79	6	ae2d2e138946535596fa30a55207f261cafda461
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	7.71e-07	178	79	6	edc7143dc9959d36057cb9471681a23afcbc8cce
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	8.23e-07	180	79	6	cea079bc02e08c46600eed05ab9924ec90e1e3d3
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	8.23e-07	180	79	6	e3877f6ef5f54ff689058b4c996ab1851822f871
ToppCell	BAL-Severe-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-49 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-66	8.23e-07	180	79	6	6a777a308fa3160d31eda468db930e71862020b2
ToppCell	COVID-19-kidney-Podocyte\|kidney / Disease (COVID-19 only), tissue and cell type	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	9.06e-07	183	79	6	fb5e2a31b560126e1c04a386c24c365901c60ad7
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	9.06e-07	183	79	6	612d93df03252d4d2ccdce5a9bc162cfd9172a1a
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	9.06e-07	183	79	6	eb559ae3ae252d9365c24ef557dd49b78ed6d898
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	9.06e-07	183	79	6	7c4b775f351794a3de06bd503eecbc8ae8577c44
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	9.35e-07	184	79	6	7294b379ce4cb8fa75e432559082f93cd106aaf5
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_B-Plasma_Cell-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	9.65e-07	185	79	6	0fff2608f507e019ebb69c27e58fd5be3b049bef
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_B-Plasma_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	9.65e-07	185	79	6	79edc1eeb7b5b9123961ac3ecf398ee68d9dddb9
ToppCell	kidney_cells-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK5 NEBL PDE4DIP KIRREL1 PTGER4 ALS2CL	1.03e-06	187	79	6	24c2a3962da364e46e98abeab5f8234376fa26bb
ToppCell	healthy_donor-Lymphocytic-Plasma_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-66	1.06e-06	188	79	6	bd53b0371154cff680226897b61c9809a239d1b6
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-66	1.06e-06	188	79	6	6844cebca177fdf38b21a40d606230a033717a3a
ToppCell	PND07-28-samps-Mesenchymal-Matrix_fibroblast\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	GPC1 COL5A2 STBD1 NEBL MRC2 GRIA3	1.09e-06	189	79	6	dc5164591dea45b420798b94dda211be03daa70c
ToppCell	PND07-28-samps-Mesenchymal-Matrix_fibroblast-FB-3\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	GPC1 COL5A2 STBD1 NEBL MRC2 GRIA3	1.13e-06	190	79	6	1196b8ea2c44c7c80f5ee589dd517e6a413f2077
ToppCell	5'-Adult-LargeIntestine-Hematopoietic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	1.16e-06	191	79	6	d1d30279ed4612b4f62c225d9eabf0b8a7a09d11
ToppCell	COVID-19-Lymphoid-Plasma,_B_cells\|COVID-19 / Condition, Lineage and Cell class	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-66	1.24e-06	193	79	6	bffd97a73365e1dd23ff3b0320b4860f04ec091a
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.24e-06	193	79	6	bcda1fb3db7d4c276e3370250a2b79fedd807fc5
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.24e-06	193	79	6	befab58da635723db4f9270d087afa981fc45bf1
ToppCell	Control-B_cell-B_cell\|Control / Disease group,lineage and cell class （2021.01.30）	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.24e-06	193	79	6	d43099c0b8ca68048d6497c4db89d6d5155375f9
ToppCell	BAL-Control-Lymphocyte-B-B_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.24e-06	193	79	6	ba826e6e035e48e1b497af1081c43339b0019e76
ToppCell	Control-B_cell\|Control / Disease group,lineage and cell class （2021.01.30）	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.27e-06	194	79	6	8388fe4df3461d85b21bd6847a4d32c030aaece4
ToppCell	BAL-Control-Lymphocyte-B\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.27e-06	194	79	6	1537e2285d0a8d0a4175dd0b8b1d1ccd887229fc
ToppCell	Parenchymal-10x3prime_v2-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-66	1.31e-06	195	79	6	2d18f08f33f3b261c77b8adf87d1a184cc6d7400
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-B-B_plasma\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	1.31e-06	195	79	6	0b0615553b9a1b60d666d074ce4260919e2d5642
ToppCell	COVID_non-vent-Lymphocytic-T_cell-CD4+_Memory_T_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	CYLD CD3G MAST4 DOCK9 PDE4DIP ALS2CL	1.31e-06	195	79	6	22191d361af136942508f1553ff41a626ed982ad
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell-B_mature\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20	1.35e-06	196	79	6	c2e17f3b2217f20bd7f28a1db4aa7d9a95c52a9c
ToppCell	COVID-19-Fibroblasts-Intermediate_pathological_FB\|COVID-19 / group, cell type (main and fine annotations)	COL5A2 NEBL PDGFRA MRC2 ST6GALNAC5 NAV3	1.39e-06	197	79	6	f1c8936986123a3151140c374fcd62d6705c530b
ToppCell	COVID_vent-Lymphocytic-Plasma_cell\|COVID_vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	1.43e-06	198	79	6	e84c5f712e1dea548d0e2aba6625598f9671d3a0
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell-B_naive\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	1.43e-06	198	79	6	79c690d21d3420d0bb1a3b3b4ea2c9aa3810a219
ToppCell	Control-Control-Lymphocyte-B-Plasmablast\|Control / Disease, condition lineage and cell class	IGHV3-49 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.48e-06	199	79	6	c11aa8bca3723a886e7082ae48bb922dd8396be4
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_cell-B_naive\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-23 IGHV3-21 IGHV3-20 RGS7	1.48e-06	199	79	6	8e02d3a066e79e0f2024a10738e0ea070513ef19
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-CD4+_T_activated\|COVID-19_Mild / Disease, condition lineage and cell class	CYLD CD3G MAST4 DOCK9 ALS2CL ADAR	1.52e-06	200	79	6	d9e8a0d047d4403fb7265fde7448e23a7780785c
ToppCell	metastatic_Lymph_Node-B_lymphocytes-Plasma_cells\|metastatic_Lymph_Node / Location, Cell class and cell subclass	IGHV3-49 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21	5.45e-06	142	79	5	5ba3a33c2ee20be8baaed97536ca6e9d1de6752f
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Neuronal-cortical_neurons_1\|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.	KIRREL1 GRIA2 GDPGP1 SH3RF3 RGS7	9.16e-06	158	79	5	1f94622186d8329357fa06785e03eeacf29ab1ce
ToppCell	368C-Lymphocytic-Plasma_cell-\|368C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-66	1.03e-05	162	79	5	c21a54310b239d999bbc9d8fb5e8fda16e0bc336
ToppCell	368C-Lymphocytic-Plasma_cell\|368C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-66	1.03e-05	162	79	5	f945688815229c8386cbcbf46deee7df316fa8d3
ToppCell	healthy_donor-Lymphocytic-Plasma_cell-IgM_Plasmablast\|healthy_donor / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-23 IGHV3-66	1.16e-05	166	79	5	2b7b580bec8d9467b0deaf97098065f72dbf2a4f
ToppCell	3'_v3-Lung-Lymphocytic_B_plasma\|Lung / Manually curated celltypes from each tissue	IGHV3-33 IGHV3-30 STAB2 IGHV3-23 IGHV3-66	1.27e-05	169	79	5	a65853ff9f6489cc1617cbba0d03b392d23c1528
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell-B_activate-7\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.31e-05	170	79	5	ee2ee67d90ae4596de8ccd620e37c82cf51651d4
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.31e-05	170	79	5	d7ca0c6ce5d2b7de99346f87e07aa7fe728fa08a
ToppCell	BAL-Mild-Lymphocyte-B-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21	1.31e-05	170	79	5	52787f6d529c285d9f0c04cc022710ead5b89b3f
Drug	Nifenazone [2139-47-1]; Down 200; 13uM; PC3; HT_HG-U133A	GPC1 DOCK5 CACTIN MAST4 NAV3 HCFC1 AQR ITPR1	1.68e-07	195	71	8	2122_DN
Drug	Sulfaguanidine [57-67-0]; Up 200; 18.6uM; MCF7; HT_HG-U133A	GPC1 CYLD COL5A2 STAB2 FMO4 PRSS22 AQR ITPR1	1.75e-07	196	71	8	1495_UP
Drug	LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A	GPC1 CYLD COL5A2 FMO4 NEBL PDE4DIP CWC25 AQR	1.89e-07	198	71	8	6935_UP
Drug	Methazolamide [554-57-4]; Down 200; 17uM; PC3; HT_HG-U133A	FMO4 AGO4 NEBL PRSS22 NAV3 KIRREL1 RGS7	2.45e-06	194	71	7	5794_DN
Drug	Celecoxib	DECR1 NAV3 GRIA2 GRIA3 GRIN1 GRIN3A LCT PTGER4 ADAR	2.51e-06	376	71	9	ctd:D000068579
Drug	Naringin hydrate [11032-30-7]; Up 200; 6.6uM; HL60; HT_HG-U133A	GPC1 COL5A2 STAB2 NEBL SIGLEC8 MRC2 PDE4DIP	2.54e-06	195	71	7	2425_UP
Drug	Nifurtimox [23256-30-6]; Down 200; 14uM; PC3; HT_HG-U133A	CYLD NEBL MRC2 PDE4DIP ALS2CL HCFC1 AQR	2.81e-06	198	71	7	6608_DN
Drug	Repaglinide [135062-02-1]; Up 200; 8.8uM; PC3; HT_HG-U133A	DOCK5 CACTIN STAB2 AGO4 HDAC6 NEBL ITGA7	2.81e-06	198	71	7	5862_UP
Drug	memantine	PTPA GRIA2 GRIA3 GRIN1 GRIN3A	7.32e-06	86	71	5	CID000004054
Drug	2-Chloro-4-fluorobenzoate	DECR1 MGAM	9.59e-06	2	71	2	CID000075259
Drug	2-deoxy-6-phosphogluconate	DECR1 PGD	9.59e-06	2	71	2	CID000188314
Drug	butylethanolamine	PHKA2 MGAM PTPA	1.58e-05	16	71	3	CID000249006
Drug	diphenylcarbazide	DSP IL4I1 HCFC1	2.29e-05	18	71	3	CID000008789
Drug	AC1L1A5Z	DECR1 PTPA GRIA2 GRIA3 PGD	2.53e-05	111	71	5	CID000000850
Drug	pioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A	DOCK5 CYLD COL5A2 PDE4DIP HCFC1 ITPR1	2.85e-05	190	71	6	7528_DN
Drug	AC1L9ALX	DECR1 MGAM	2.87e-05	3	71	2	CID000441134
Drug	2-aminocyclohexanol	DECR1 MGAM	2.87e-05	3	71	2	CID000023286
Drug	AC1L4WHE	DECR1 MGAM	2.87e-05	3	71	2	CID000193533
Drug	Butamben [94-25-7]; Down 200; 20.6uM; PC3; HT_HG-U133A	CYLD NEBL PDE4DIP NAV3 CSPP1 RGS7	2.93e-05	191	71	6	5792_DN
Drug	e511	DECR1 MGAM PGD	3.19e-05	20	71	3	CID000024644
Drug	Carbarsone [121-59-5]; Up 200; 15.4uM; MCF7; HT_HG-U133A	HDAC6 CYP3A43 DOCK9 PDE4DIP DGKG ITGA7	3.20e-05	194	71	6	4110_UP
Drug	Myricetin [529-44-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A	DOCK5 CYLD STAB2 PDE4DIP HCFC1 ITPR1	3.30e-05	195	71	6	4170_DN
Drug	Mephenytoin [50-12-4]; Up 200; 18.4uM; HL60; HT_HG-U133A	GPC1 STAB2 HDAC6 DOCK9 GRIA3 GRIN1	3.39e-05	196	71	6	6158_UP
Drug	Tracazolate hydrochloride [41094-88-6]; Down 200; 11.8uM; PC3; HT_HG-U133A	GPC1 CYLD AGO4 NAV3 KIRREL1 ALS2CL	3.39e-05	196	71	6	6619_DN
Drug	Etanidazole [22668-01-5]; Up 200; 18.6uM; HL60; HT_HG-U133A	GPC1 NEBL SIGLEC8 MRC2 CYP3A43 DGKG	3.39e-05	196	71	6	2510_UP
Drug	Bicuculline (+) [485-49-4]; Up 200; 10.8uM; PC3; HT_HG-U133A	PDGFRA SIGLEC8 PDE4DIP ITGA7 PTGER4 HCFC1	3.39e-05	196	71	6	4574_UP
Drug	Folic acid [59-30-3]; Down 200; 9uM; MCF7; HT_HG-U133A	PHKA2 CACTIN PRSS22 HCFC2 CSPP1 HCFC1	3.49e-05	197	71	6	7201_DN
Drug	Ethamivan [304-84-7]; Up 200; 18uM; MCF7; HT_HG-U133A	HDAC6 NEBL GRIN1 HCFC2 HCFC1 ITPR1	3.49e-05	197	71	6	7021_UP
Drug	Sulfinpyrazone [57-96-5]; Up 200; 9.8uM; PC3; HT_HG-U133A	AGO4 CYP3A43 PDE4DIP PRSS22 ITGA7 PTGER4	3.49e-05	197	71	6	5753_UP
Drug	Gliquidone [33342-05-1]; Down 200; 7.6uM; PC3; HT_HG-U133A	COL5A2 AGO1 PDE4DIP NAV3 HCFC1 ITPR1	3.49e-05	197	71	6	7301_DN
Drug	Carteolol hydrochloride [51781-21-6]; Down 200; 12.2uM; PC3; HT_HG-U133A	GPC1 STAB2 NEBL PDE4DIP PRSS22 CSPP1	3.49e-05	197	71	6	4096_DN
Drug	Milrinone [78415-72-2]; Up 200; 19uM; MCF7; HT_HG-U133A	GPC1 DOCK5 MAST4 DOCK9 HCFC1 AQR	3.59e-05	198	71	6	7210_UP
Drug	Glibenclamide [10238-21-8]; Down 200; 8uM; PC3; HT_HG-U133A	DOCK5 COL5A2 MAST4 NAV3 KIRREL1 ITPR1	3.59e-05	198	71	6	5849_DN
Drug	Paromomycin sulfate [1263-89-4]; Up 200; 5.6uM; HL60; HT_HG-U133A	DOCK5 CACTIN HDAC6 PRSS22 PTGER4 ALS2CL	3.59e-05	198	71	6	3017_UP
Drug	Pinacidil [85371-64-8]; Up 200; 16.4uM; PC3; HT_HG-U133A	CYLD CACTIN AGO4 PDE4DIP GRIN1 ITGA7	3.59e-05	198	71	6	6356_UP
Drug	Diphenhydramine hydrochloride [147-24-0]; Up 200; 13.8uM; MCF7; HT_HG-U133A	CYLD STAB2 MAST4 HDAC6 PDE4DIP ITPR1	3.69e-05	199	71	6	6020_UP
Drug	S(-)Eticlopride hydrochloride [97612-24-3]; Up 200; 10.6uM; HL60; HT_HG-U133A	COL5A2 PDGFRA SIGLEC8 CYP3A43 PDE4DIP GRIA3	3.80e-05	200	71	6	3056_UP
Drug	anisamide	GRIA2 GRIA3 LCT	4.29e-05	22	71	3	CID000075540
Drug	nimbidiol	MGAM LCT	5.73e-05	4	71	2	ctd:C496111
Drug	3-pyridazinol 1-oxide	GRIA2 GRIA3	5.73e-05	4	71	2	CID000574311
Drug	phytenic acid	DECR1 MGAM	5.73e-05	4	71	2	CID005282676
Drug	Aniracetam	GRIA2 GRIA3	5.73e-05	4	71	2	DB04599
Drug	L-Glutamic Acid	GRIA2 GRIA3 GRIN1 GRIN3A	6.08e-05	68	71	4	DB00142
Drug	NSC406942	DECR1 MGAM GRIA2 GRIA3 ERP29 LCT DNAH9 AKAP8L ITPR1	6.35e-05	565	71	9	CID000001115
Drug	benzoate	DECR1 TIGD7 LTA4H HCFC2 ITGA7 IL4I1	6.61e-05	221	71	6	CID000000242
Drug	AC1Q5PO8	DECR1 MGAM ITPR1	9.00e-05	28	71	3	CID000000642
Drug	AC1L1YEG	GRIA2 GRIA3	9.53e-05	5	71	2	CID000063114
Drug	Chicago acid	GRIA2 GRIA3	9.53e-05	5	71	2	CID000065740
Drug	CHEBI:570577	GRIA2 GRIA3	9.53e-05	5	71	2	CID011334126
Drug	1-BCP	GRIA2 GRIA3	9.53e-05	5	71	2	CID000001370
Drug	irampanel	GRIA2 GRIA3	9.53e-05	5	71	2	CID003038472
Drug	selenium chloride	PDGFRA PGD	9.53e-05	5	71	2	CID000066206
Drug	LY395153	GRIA2 GRIA3	9.53e-05	5	71	2	CID000656707
Drug	beta-N-oxalylaminoalanine	GRIA2 GRIA3	9.53e-05	5	71	2	CID000107978
Drug	5-h PCA	GRIA2 GRIA3	9.53e-05	5	71	2	CID000129091
Drug	dinophysistoxin-1	DOCK5 PHKA2 PTPA	1.23e-04	31	71	3	CID006437058
Drug	alpha-methyl-4-carboxyphenylglycine	GRIA2 GRIA3 ITPR1	1.35e-04	32	71	3	CID000001222
Drug	phytate	MGAM GRIA2 GRIA3 ADAR ITPR1	1.40e-04	159	71	5	CID000000890
Drug	YM928	GRIA2 GRIA3	1.43e-04	6	71	2	CID006918393
Drug	N-ethyl-N-methylaniline	DECR1 FMO4	1.43e-04	6	71	2	CID000011956
Drug	2cmo	GRIA2 GRIA3	1.43e-04	6	71	2	CID006914597
Drug	AC1LIZYF	GPC1 DOCK5 MGAM PTPA DNAH9	1.86e-04	169	71	5	CID000914489
Drug	PTAD	PHKA2 MGAM	1.99e-04	7	71	2	CID000077913
Drug	AC1L1BIH	DECR1 PTGER4	1.99e-04	7	71	2	CID000001453
Drug	Orphenadrine	GRIN1 GRIN3A	1.99e-04	7	71	2	DB01173
Drug	4,6-dichloroindole-2-carboxylic acid	GRIA2 GRIA3	1.99e-04	7	71	2	CID000127988
Drug	thio-ATPA	GRIA2 GRIA3	1.99e-04	7	71	2	CID005289517
Drug	Ro 24-4736	DECR1 LTA4H	1.99e-04	7	71	2	CID000060775
Drug	myo-inositol	GPC1 CD3G PDGFRA DGKG LTA4H DSEL LCT PTGER4 RGS7 ITPR1	2.01e-04	811	71	10	CID000000892
Drug	AC1L1BEQ	DECR1 PTPA CYP3A43 LTA4H	2.06e-04	93	71	4	CID000001407
Drug	gamma-Glu-Gly	MGAM GRIA2 GRIA3	2.09e-04	37	71	3	CID000100099
Drug	AC1MHEDK	XIRP1 CD3G GRIN1 ADAR	2.14e-04	94	71	4	CID003002889
Drug	K-K-K	DECR1 PTPA FMO4 CYP3A43 LTA4H	2.19e-04	175	71	5	CID000003823
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	HDAC6 PDGFRA PDE4DIP ITGA7 PTGER4	2.19e-04	175	71	5	3746_UP
Drug	GAMs	MGAM GRIA2 GRIA3	2.27e-04	38	71	3	CID000002935
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	NEBL PDGFRA PDE4DIP PTGER4 ITPR1	2.43e-04	179	71	5	4184_UP
Drug	11,14,15-THET	DECR1 CYP3A43 LTA4H	2.45e-04	39	71	3	CID006439531
Drug	DETC-MeSO	DECR1 GRIA2 GRIA3	2.45e-04	39	71	3	CID003035711
Drug	AC1Q6S7C	DECR1 MGAM PGD	2.45e-04	39	71	3	CID000000616
Drug	ethanol	DECR1 DOCK5 MGAM PTPA GRIA2 GRIA3 GRIN3A PTGER4 PGD ITPR1	2.59e-04	837	71	10	CID000000702
Drug	indeloxazine	MGAM GRIN1	2.65e-04	8	71	2	CID000003704
Drug	homoibotenic acid	GRIA2 GRIA3	2.65e-04	8	71	2	CID000194385
Drug	1-hydroxypyrazole	GRIA2 GRIA3	2.65e-04	8	71	2	CID003016733
Drug	1-hydroxyimidazole	GRIA2 GRIA3	2.65e-04	8	71	2	CID003614351
Drug	2,3-PDCA	GRIA2 GRIA3	2.65e-04	8	71	2	CID000127037
Drug	9 mM of H	MGAM ITPR1	2.65e-04	8	71	2	CID000130464
Drug	AC1L9QQ8	PTPA IL4I1	2.65e-04	8	71	2	CID000453060
Drug	NSC374898	DECR1 MGAM	2.65e-04	8	71	2	CID005351331
Drug	NSC633676	DECR1 LTA4H	2.65e-04	8	71	2	CID000133894
Drug	MS-275; Up 200; 10uM; PC3; HT_HG-U133A	MAST4 PDGFRA NAV3 PTGER4 RGS7	2.69e-04	183	71	5	7084_UP
Drug	Forskolin, from Coleus forskohlii; Up 200; 0.5uM; MCF7; HT_HG-U133A	DOCK5 PHKA2 NEBL PDE4DIP ITPR1	2.83e-04	185	71	5	7055_UP
Drug	trichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A	CYLD PDE4DIP ITGA7 AQR ITPR1	2.97e-04	187	71	5	5976_UP
Drug	Ampyrone [83-07-8]; Down 200; 19.6uM; PC3; HT_HG-U133A	DOCK5 CYLD PDE4DIP KIRREL1 CSPP1	3.20e-04	190	71	5	4507_DN
Drug	Clonidine hydrochloride [4205-91-8]; Down 200; 15uM; MCF7; HT_HG-U133A	DOCK5 CACTIN DOCK9 PRSS22 HCFC1	3.20e-04	190	71	5	3172_DN
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	CYLD PDGFRA PDE4DIP GRIA3 PTGER4	3.28e-04	191	71	5	4302_UP
Drug	Alprenolol hydrochloride [13707-88-5]; Down 200; 14uM; MCF7; HT_HG-U133A	CYLD NEBL PDE4DIP ALS2CL CSPP1	3.36e-04	192	71	5	3188_DN
Drug	pioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A	COL5A2 PDGFRA PDE4DIP NAV3 ALS2CL	3.36e-04	192	71	5	5930_DN
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A	CYLD NEBL SIGLEC8 CYP3A43 DOCK9	3.36e-04	192	71	5	2523_UP
Drug	1m5b	GRIA2 GRIA3	3.40e-04	9	71	2	CID000447081
Drug	ZK 118.182	PTGER4 PGD	3.40e-04	9	71	2	CID006439073
Disease	Bipolar Disorder	PTPA DOCK9 GRIA2 GRIA3 GRIN1 GRIN3A ITPR1	1.95e-04	477	74	7	C0005586
Disease	cysteine measurement	FMO4 NAV3	2.21e-04	9	74	2	EFO_0021000
Disease	Situs Inversus	DNAH9 ANKS3	3.36e-04	11	74	2	C0037221
Disease	congenital heart disease (implicated_via_orthology)	HCFC2 HCFC1 ITPR1	7.04e-04	69	74	3	DOID:1682 (implicated_via_orthology)
Disease	central nervous system disease (implicated_via_orthology)	GRIA2 GRIA3	7.28e-04	16	74	2	DOID:331 (implicated_via_orthology)
Disease	intestinal permeability measurement	STAB2 GRIN3A	1.94e-03	26	74	2	EFO_0011031
Disease	sensory perception of bitter taste	MGAM SH3RF3	1.94e-03	26	74	2	GO_0050913
Disease	cholesteryl ester 14:0 measurement	NAV3 RGS7	2.09e-03	27	74	2	EFO_0010340

Protein segments in the cluster

Peptide	Gene	Start	Entry
ERYIGMWQAGQRHGP	ALS2CL	481	Q60I27
ARAWENLGEQMGKAP	ADAD2	81	Q8NCV1
KWNLGSNAKDPRGMY	CD3G	71	P09693
DWMYQGPGGMVNRDE	CWC25	71	Q9NXE8
IQRWLKGQGVYLGMP	ERP29	141	P30040
ATPNQGVWDMRGKQF	AGO1	426	Q9UL18
RYGPSLMPGGNKEAW	PGD	136	P52209
RMKPWQSEYGGVVFG	AQR	491	O60306
TPNQGVWDMRGKQFY	AGO4	421	Q9HCK5
GGVSEGQMKQVAWPE	AGO4	671	Q9HCK5
GYGRMWEDPMGARGQ	AKAP8L	196	Q9ULX6
MLKIAEDLGGPYVWG	LTA4H	241	P09960
QWTYPGEVKGKGITM	PDGFRA	246	P16234
TTIGNKMYVFGGWVP	HCFC1	261	P51610
NYMSWVRQAPGKGLE	IGHV3-66	51	A0A0C4DH42
SVIGNKMYIFGGWVP	HCFC2	251	Q9Y5Z7
YGMHWVRQAPGKGLE	IGHV3-30-5	51	P0DP03
IMGSWNPVGVGRYLN	LEXM	346	Q3ZCV2
EGFQPLGEVIKMWGR	GIGYF1	516	O75420
RVPVIKMGTGWEGFQ	LENEP	26	Q9Y5L5
LWVYKGQGPDETMDG	ITPR1	1141	Q14643
FQEKGEWGYMPTLRN	MST1L	106	Q2TV78
WNGMARGRYLPEVMG	GPC1	416	P35052
GPYDRGSDMKIWVNS	MGAM	466	O43451
LYWRGAGQGPITEDM	PRSS22	211	Q9GZN4
YGGGSMWEQAKALQE	DDX42	361	Q86XP3
YEMNWVRQAPGKGLE	IGHV3-48	51	P01763
NGPRKIGYWSEVDKM	GRIA2	381	P42262
GARDPETKIWNGMVG	GRIA3	481	P42263
MKGQWPGGQPLCEYS	PTGER4	81	P35408
GLQMYGKRTPWEDPS	NAV3	2276	Q8IVL0
LEAEMRTYNPWGKGG	CSPP1	661	Q1MSJ5
YRLMGPGKWDGARNA	FMO4	471	P31512
NGDYPDTMKWKVGNR	LCT	1161	P09848
GMNFNPKGGTLVWQD	MRC2	1331	Q9UBG0
YGQKDLMAEGIQWPR	GDPGP1	31	Q6ZNW5
YGMSWVRQAPGKGLE	IGHV3-20	51	A0A0C4DH32
RKGNMTLSPENGYWV	MEFV	676	O15553
YAMSWVRQAPGKGLE	IGHV3-49	51	A0A0A0MS15
YSMNWVRQAPGKGLE	IGHV3-21	51	A0A0B4J1V1
SPGKNATGMEVGWYR	MOG	56	Q16653
GGKIVMDYGIWPEQA	GRIN3A	486	Q8TCU5
AEWGKYGMRFNVIQP	DECR1	226	Q16698
PSMYGGTNLWGENKK	DGKG	661	P49619
ENYLIRWGSNGMPKE	DOCK5	256	Q9H7D0
LGMGRHYGPEIKWVD	DOCK9	791	Q9BZ29
EKYGEMWGLYEGQQP	CYP3A43	66	Q9HB55
MGYGNWISKPQEEKN	ADAR	1206	P55265
SKWYVTGPGGVDMLV	DSP	491	P15924
DNKPVWYGLDMNRGS	COL5A2	1356	P05997
YAMSWVRQAPGKGLE	IGHV3-23	51	P01764
YGMHWVRQAPGKGLE	IGHV3-30	51	P01768
YTQTQAMEKAWAPGG	MAST4	2026	O15021
DLNKKNGGGWTPLMY	ANKS3	61	Q6ZW76
GMGQGLKAWPRYRVV	KIRREL1	61	Q96J84
RAGGPNLDMGYWESL	CACTIN	426	Q8WUQ7
MAHYLKVREVGGWGP	DCAF12L1	51	Q5VU92
GKWLLYPMQVELEGG	ITGA7	916	Q13683
NGIGEPKYMPVQSWE	DNAH9	2761	Q9NYC9
VNVAWNGPRMGDADY	HDAC6	701	Q9UBN7
GVDMDNPIGNWDGRF	CYLD	266	Q9NQC7
RMVGYKDWLVENAPG	DSEL	151	Q8IZU8
YGMWERGDKTNQGIP	PHKA2	181	P46019
YGMHWVRQAPGKGLE	IGHV3-33	51	P01772
NYMSWVRQAPGKGLE	IGHV3-53	51	P01767
YRDQNTGWIGELGAM	IL4I1	101	Q96RQ9
GRPENCGQIYWRAMK	UTP6	561	Q9NYH9
EPSQQRVKRWGFGMD	RGS7	321	P49802
LWGTKGMEGDRQYGD	SIGLEC8	11	Q9NYZ4
WGPSSYMRRDGKGQV	ST6GALNAC5	171	Q9BVH7
GKVGPMIGQYVDSQW	WDR45	281	Q9Y484
GRGAVWGSVIYPSMK	TTLL8	486	A6PVC2
MPGKAPAVWGQDGYS	RBMXL3	221	Q8N7X1
LESPMGEWGFQKGQE	STBD1	146	O95210
QKTYRMEPAGSQGVW	PTPA	231	Q15257
NWAEGMLGDKIGIFP	SH3RF3	296	Q8TEJ3
GIVDYGPRPNKSEMW	STAB2	2271	Q8WWQ8
MWYQQKRSAGVPVRG	TIGD7	86	Q6NT04
GGDVQGYRWMFETQP	XIRP1	506	Q702N8
EPGYLGSSGKWDVMR	PDE4DIP	1801	Q5VU43
PIDDGWMYGTVQRTG	NEBL	986	O76041
WPGGETEKPRGYQMS	GRIN1	381	Q05586